Click here to access the guidelines/NICE algorithm

N&WICS - TA327 - Dabigatran etexilate - treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism						
Before providing patient identifiable data on this form, please confirm that the patient (or in the case of a minor or vulnerable adult with the parent/legal guardian/carer) has given appropriate explicit consent for sensitive personal information on this form to be passed to the CCG and/or CSU for processing this funding request and validating subsequent invoices. Consent given:						
If there is more than one NICE-approved treatment available, a discussion between the responsible clinician and the patient has taken place about the advantages and disadvantages of the treatments available. This has taken into consideration therapeutic need and whether or not the patient is likely to adhere to treatment. The most appropriate, least expensive, will be chosen (taking into account administration costs, dosage						
and price per dose) unless an order of preference is stated in the TAs.						
Patient NHS No:	Trust:			Practice Name:		
Patient Hospital No:	Consultant Making Request:			Practice Postcode:		
Patient's Initials and DoB:				Practice Code:		
Notification Email Address:		(@NHS.ne	t account ONLY)	Contact name & number:		
Start date	Provider:	□ Private	e □NHS			
of requested treatment:	Supplier:	_	care Hospital	Sub-Type:	/A 🔽	
For support regarding IFRs, please contact: norfolkicd@nhs.net For support regarding the criteria listed below, please contact: norfolknontariff@nhs.net						
Please indicate whether patient meets the following NICE criteria:					Please tick	
1. Dabigatran etexilate is recommended, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.					□Yes □No	
2. As per NICE guidance, treatment should normally be started with the least expensive drug (considering the dose required, price per dose and any additional administration costs).						
Please confirm that the choice of drug is considered the most cost-effective treatment for this individual patient, noting that alternative treatment options recommended by NICE may be lower in cost, including the use of biosimilar medications if applicable.					☐Yes ☐No	
Where an alternative lower cost treatment is available and has not been tried by the patient, please confirm that the clinical rationale for prescribing has been included in the patients' medical record for the purpose of auditing.						
I confirm that the patient meets	s the criteria for tr	eatment				
Name of person completing:			Contact Details:			
Designation of person completing:			Date:			
Trust Authorising Pharmacist						
Name:						
Date:						